Form 4: Orthofix Executive Sells Shares to Cover Tax Obligations from RSU Settlement
Insider Transaction Report
Aviva McPherron, President of Global Operations & Quality at Orthofix Medical Inc., sold 3,728 shares of common stock for tax withholding purposes related to restricted stock unit settlement.
Summary
- Aviva McPherron, President, Global Operations & Quality of Orthofix Medical Inc. (OFIX), reported a transaction on June 18, 2025.
- The transaction involved the sale of 3,728 shares of Orthofix common stock at a price of $10.51 per share.
- This sale was conducted to satisfy tax withholding obligations associated with the settlement of restricted stock units (RSUs).
- The sale was a pre-existing 'sell-to-cover' requirement, previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors.
- The reporting person, Aviva McPherron, exercised no discretion in this sale.
- Following this transaction, Aviva McPherron beneficially owns 46,322 shares of Orthofix common stock, which includes 37,557 previously reported restricted stock units.
Sentiment
Score: 5
Explanation: The transaction is a routine 'sell-to-cover' for tax purposes, which is a non-discretionary sale and generally considered neutral in terms of sentiment. It does not reflect a change in management's outlook on the company.
Future Outlook
N/A
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction, specifically a 'sell-to-cover' sale, which is common practice in executive compensation plans across various industries, including the medical device sector where Orthofix operates. It does not provide broader industry trends or competitive insights.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Plan Oversight | The sale was pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors, which administers the restricted stock unit plan. | N/A | This demonstrates adherence to established corporate governance procedures for executive compensation and tax compliance related to equity awards. |
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in insider ownership, but as it's for tax purposes and non-discretionary, it typically has minimal implications for shareholder confidence or company valuation.
Key Dates
| Date | Description |
|---|---|
| 06/18/2025 | Date of transaction (sale of common stock) |
| 06/23/2025 | Date the Form 4 was filed |
Keywords
Orthofix Medical Inc., OFIX, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Executive Compensation, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.